The efficacy and toxicity of VAD in the treatment of myeloma and related disorders
- 1 November 1986
- journal article
- research article
- Published by Wiley in Scandinavian Journal of Haematology
- Vol. 37 (5) , 425-428
- https://doi.org/10.1111/j.1600-0609.1986.tb02632.x
Abstract
Impressive results have recently been reported in 29 cases of advanced refractory myeloma treated with 4-d infusions of Vincristine and Adriamycin (VAD). We report our own experience with this protocol in 13 cases of myeloma and relmphoproliferative disorders. In 2 of these cases, VAD was used as first line treatment. Objective responses were seen in two-thirds of cases and the major complication of therapy was infection, predominantly bacterial in nature.Keywords
This publication has 7 references indexed in Scilit:
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsNew England Journal of Medicine, 1984
- High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myelomaCancer, 1984
- Serum beta2microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.British Journal of Haematology, 1983
- HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMAThe Lancet, 1983
- Prednisone pulse therapy for refractory myelomaBlood, 1983
- PREDNISONE PULSE THERAPY FOR REFRACTORY MYELOMA1983
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975